– Dragonfly Therapeutics anuncia la publicación de datos preclínicos que respaldan a DF6002, su citoquina IL-12 de vida media extendida, como un tratamiento prometedor para el cáncer La publicación titulada “Una IL-12-Fc optimizada amplía su ventana terapéutica, logrando una fuerte…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.